At a glance
ClinicalIndex Comparison RecordN/ACompleted· 82 enrolled
Drug / intervention
Laser Atherectomydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Turbo Power Laser Atherectomy Combined With Drug Coated Balloon Angioplasty for the Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
In Brief
An observational study evaluating Laser Atherectomy for Peripheral Arterial Disease. Completed, enrolled 82 participants across 1 site.
Detailed Summary
A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedOct 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedOct 10, 2017
Enrollment StartOct 3, 2017
Primary CompletionJun 5, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.7 years ago
Interventions
Laser Atherectomydevice
The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).